Nama Insights

Jade Biosciences (JBIO)

Healthcare · Biotechnology · NASDAQ

Jade Biosciences (JBIO) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.04B and a free-cash-flow yield of -15.8%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the middle band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 20, 2026.
Momentum
Middle · +31.8% over 12 months ex. last
Middle fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-98.7%
How far the last close sits under the highest price of the past five years.
Market cap$1.04B
Trailing P/E—
Price / book2.2
Price / sales—
FCF yield-15.8%
Dividend yield—
Gross margin0.0%
Operating margin0.0%
Net margin0.0%
Revenue growth (YoY)—
Revenue growth (3-yr annual)—
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta—
ExchangeNASDAQ
SectorHealthcare
IndustryBiotechnology

JBIO earnings

Next report: Mar 4, 2027 (Q4 2026, EPS estimate -$0.41). Beat the EPS estimate in 2 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 13, 2026 -$0.42 -$0.79 +46.8% $0
Q2 2026 Aug 10, 2026 -$0.76 -$0.54 -40.7% $0
Q1 2026 May 7, 2026 -$0.57 -$0.48 -18.8% $0
Q3 2025 Nov 12, 2025 -$0.48 -$0.67 +28.4% $0

JBIO analyst price target

Median target $46.00 from 8 analysts, ranging $40.00 – $77.00.

Biotechnology peers

TickerCompanyMarket capP/E
VRTX Vertex Pharmaceuticals $132.01B 27.4
REGN Regeneron Pharmaceuticals $95.52B 16.7
MRNA Moderna $80.65B —
ARGX argenx $59.24B 32.9
ONC BeOne Medicines $45.66B 50.8
RPRX Royalty Pharma $38.94B 12.8
RVMD Revolution Medicines $34.48B —
INSM Insmed $31.69B —
Explore live JBIO data on Nama Insights →

JBIO FAQ

Is JBIO a buy?
Nama's AI scorecard currently rates Jade Biosciences Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does JBIO report earnings?
Jade Biosciences's next scheduled report is on Mar 4, 2027. Analysts expect EPS of -$0.41.
What is the JBIO price target?
The median analyst price target from 8 analysts is $46.00, with a range of $40.00 – $77.00.
Is JBIO Shariah compliant?
Nama's AAOIFI-style screen reads Jade Biosciences as Can't Tell. A figure the screen needs is missing, so it can't tell.